| Patents for A61K 45 - Medicinal preparations containing active ingredients not provided for in groups (115,020) |
|---|
| 04/25/2001 | EP1094075A1 Human G-protein coupled receptor |
| 04/25/2001 | EP1093819A2 Compounds and compositions for delivering active agents |
| 04/25/2001 | EP1093814A1 Use of dipyridamole or mopidamol in the manufacture of a medicament for the treatment and prevention of fibrin-dependent microcirculation disorders |
| 04/25/2001 | EP1093812A2 Amoxycillin and clavulanate containing pharmaceutical formulation |
| 04/25/2001 | EP1093811A1 Anti-tumor compositions containing taxan derivatives |
| 04/25/2001 | EP1093580A1 Diagnosis of predisposition to epilepsy and monitoring of antiepileptic treatment |
| 04/25/2001 | EP1093465A2 Method for producing or enhancing a t-cell response against a target cell using a complex comprising an hla class i molecule and an attaching means |
| 04/25/2001 | EP1093455A1 Bis-indole derivatives and their use as antiinflammatory agents |
| 04/25/2001 | EP1093380A2 Component b as angiogenic agent in combination with human growth factors |
| 04/25/2001 | EP1093379A2 Use of inhibitors of protein kinase c epsilon to treat pain |
| 04/25/2001 | EP1093378A1 Compositions and methods for prevention and treatment of uncontrolled formation of intravascular fibrin clots |
| 04/25/2001 | EP1093370A1 Pharmaceutical composition for the treatment of diabetes |
| 04/25/2001 | EP1093369A2 Agents with an antidepressive effect |
| 04/25/2001 | EP1093363A1 Methods and compositions for treatment of disorders associated with chlamydial and similar bacterial infection |
| 04/25/2001 | EP1093362A1 Treatment of anti-estrogen resistant breast cancer using rxr modulators |
| 04/25/2001 | EP1093348A1 Methods and transdermal compositions for pain relief |
| 04/25/2001 | CN1292701A Glucocorticoid receptor antagonists for treatment of dementia |
| 04/25/2001 | CN1292690A Use of alpha-RAR antagonists for inhibition of mucin secretion |
| 04/25/2001 | CN1292264A Phosphodiesterase inhibitor and its use |
| 04/25/2001 | CA2324116A1 Nk-1 receptor antagonists and eletriptan for the treatment of migraine |
| 04/24/2001 | US6222027 Molecules expressed in hippocampus |
| 04/24/2001 | US6222026 Gcp |
| 04/24/2001 | US6222014 Amino acid sequence of protein from ribonucleotide diphosphate reductase family; drug screening of bactericides and antibiotics |
| 04/24/2001 | US6221911 Reducing subcutaneous fat deposits in a subject; improving the skin condition of a subject |
| 04/24/2001 | US6221904 Administering to the subject an amount of dehydroascorbic acid |
| 04/24/2001 | US6221893 Administration of histamine for therapeutic purposes |
| 04/24/2001 | US6221887 Treatment of inflammatory disorders with NMDA antagonists and sodium channel antagonists |
| 04/24/2001 | US6221881 Nitrosated and nitrosylated phosphodiesterase inhibitor compounds, compositions and their uses |
| 04/24/2001 | US6221876 190 kda multidrug resistance protein (mrp1); 1-amino-2-hydroxyindan-6-yl)isoxazolo(3, 4-c)-1,2-dihydro-3-methyl-6-chloroquinolin-2-one derivatives |
| 04/24/2001 | US6221856 Inositol derivatives for inhibiting superoxide anion production |
| 04/24/2001 | US6221854 Method of promoting bone growth with hyaluronic acid and growth factors |
| 04/24/2001 | US6221670 Methods to identify β-amyloid reducing agents |
| 04/24/2001 | US6221667 Packaged pharmaceutical composition includes a mobile ionophore which prevents or decreases amyloid precursor protein catabolism in cells without altering cell viability in a pharmaceutical vehicle in a container, and instructions |
| 04/24/2001 | US6221660 Amino acid sequence; recombinant production; drug screening using membrane preparations |
| 04/24/2001 | US6221628 Nucleotide sequences coding preferential polypeptide for use in diagnosis and treatment atherosclerosis, ischemia, hypertension, restenosis and arterial inflammation |
| 04/24/2001 | US6221616 Detecting modulators of receptor binding protein; incubate cells with modulators and monitoring reduction in binding activity at receptor |
| 04/24/2001 | US6221613 Utilizing competitive binding to detect preferential modulator activity on receptor binding protein; incubate cells with modulators and monitor binding, detect amplification or reduction of binding to receptors |
| 04/24/2001 | US6221400 Methods of treating mammals using nanocrystalline formulations of human immunodeficiency virus (HIV) protease inhibitors |
| 04/24/2001 | US6221379 Buccal drug administration in female hormone replacement therapy |
| 04/24/2001 | US6221377 Administration media for analgesic, anti-inflammatory and anti-pyretic drugs containing nitrous oxide and pharmaceutical compositions containing such media and drugs |
| 04/24/2001 | US6221367 Exposing a biologically active agent to a complexing perturbant to reversibly transform the biologically active agent to the intermediate state and to form a transportable supramolecular complex |
| 04/24/2001 | US6221355 Anti-pathogen system and methods of use thereof |
| 04/24/2001 | US6221354 Feeding an antigen to a mammal, wherein the mammal is not allowed to ingest a fat-soluble component |
| 04/24/2001 | CA2030459C Biodegradable ocular implants |
| 04/19/2001 | WO2001027635A1 Multiwell scanner and scanning method |
| 04/19/2001 | WO2001027630A2 Methods to identify compounds that modulate neuronal activity |
| 04/19/2001 | WO2001027622A1 Crystallographic structure of the androgen receptor ligand binding domain |
| 04/19/2001 | WO2001027314A1 Antiprotozoal histone acetyl transferase inhibitors |
| 04/19/2001 | WO2001027309A1 Hiv integrase inhibitors |
| 04/19/2001 | WO2001027280A1 Antimicrobial compositions |
| 04/19/2001 | WO2001027265A1 Nucleic acid sequences of hyperplasia and tumours of the thyroid |
| 04/19/2001 | WO2001027261A2 Conjugates between a peptides and a nucleic acid analog, such as a pna, lna or a morpholino |
| 04/19/2001 | WO2001027154A2 Membrane translocating peptide drug delivery system |
| 04/19/2001 | WO2001027146A2 Chemokine receptor |
| 04/19/2001 | WO2001027143A1 Lantibiotic |
| 04/19/2001 | WO2001027140A1 Caspase inhibitors for the treatment and prevention of chemotherapy and radiation therapy induced cell death |
| 04/19/2001 | WO2001027128A1 C-aryl glucoside sglt2 inhibitors |
| 04/19/2001 | WO2001027107A2 Heterocyclic sodium/proton exchange inhibitors and method |
| 04/19/2001 | WO2001027079A2 Compositions and methods of use of ligands that bind components of the blood coagulation/clotting pathway for the treatment of cancer and angiogenic-based disease |
| 04/19/2001 | WO2001026737A2 Treatment of excessive bone or cartilage loss with an activator of ror alpha and assay for identifying such activator |
| 04/19/2001 | WO2001026686A1 Skin immune function controlling agents |
| 04/19/2001 | WO2001026685A1 Remedies for intractable wound |
| 04/19/2001 | WO2001026678A1 Short segments of dap-kinase |
| 04/19/2001 | WO2001026676A1 Methods of treating or preventing cell, tissue, and organ damage using human myeloid progenitor inhibitory factor-1 (mpif-1) |
| 04/19/2001 | WO2001026662A1 Pharmaceutical product suitable for use immunosuppressive therapy |
| 04/19/2001 | WO2001026645A1 Method for protecting normal cells from cytotoxicity of chemotherapeutic agents |
| 04/19/2001 | WO2001026642A2 Methods and compositions for treating neurobehavioral disorders |
| 04/19/2001 | WO2001026639A2 Pharmaceutical composition of ateglinide and another antidiabeticagent |
| 04/19/2001 | WO2001026635A2 Bioadhesive nanoparticulate compositions having cationic surface stabilizers |
| 04/19/2001 | WO2001026628A1 Cationic dosper virosomes |
| 04/19/2001 | WO2001026627A1 Liposome encapsulated silver salt compositions |
| 04/19/2001 | WO2001026623A2 Treatment of fatigue, head injury and stroke |
| 04/19/2001 | WO2001026606A2 Treatment of scar tissue using lipoic acid |
| 04/19/2001 | WO2001026604A2 Hair and scalp treatment method and recipes for application of this method |
| 04/19/2001 | WO2001026603A2 Mesoprogestins (progesterone receptor modulators) as a component of female contraceptives |
| 04/19/2001 | WO2001026481A1 Fish feed with increased nucleotide content |
| 04/19/2001 | WO2001026470A1 Suppressor cells for prevention and treatment of immune responses in transplantation |
| 04/19/2001 | WO2001026467A1 Methods of enhancing chemotherapy |
| 04/19/2001 | WO2001014557B1 Pd-1, a receptor for b7-4, and uses therefor |
| 04/19/2001 | WO2001001963A8 A method for the improvement of transport across adaptable semi-permeable barriers |
| 04/19/2001 | WO2000068380A3 Extracellular matrix and adhesion-associated proteins |
| 04/19/2001 | WO2000067732A3 Pharmaceutical composition, containing an antimycotic, polydocanol and salicylic acid |
| 04/19/2001 | WO2000061568A3 1,4-benzothiazepine-1,1-dioxide derivatives substituted by sugar radicals, methods for the production thereof, medicaments containing these compounds and the use thereof |
| 04/19/2001 | WO2000061132A8 Compositions containing immunotoxins and agents that inhibit dendritic cell maturation for inducing immune tolerance to a graft |
| 04/19/2001 | WO2000057187A3 Diagnosis and treatment of multiple sclerosis |
| 04/19/2001 | WO1998008546A8 Therapeutic combinations of rar antagonists and rxr agonists and use thereof |
| 04/19/2001 | DE19949897A1 Shaped article, e.g. in stick form, for controlled release of drugs in wounds or body cavities, comprising hydrophilic outer phase, lipophilic inner phase and drug, e.g. antibiotic |
| 04/19/2001 | CA2399093A1 Caspase inhibitors for the treatment and prevention of chemotherapy and radiation therapy induced cell death |
| 04/19/2001 | CA2388991A1 Conjugates between a peptides and a nucleic acid analog, such as a pna, lna or a morpholino |
| 04/19/2001 | CA2388813A1 Heterocyclic sodium/proton exchange inhibitors and method |
| 04/19/2001 | CA2388253A1 Crystallographic structure of the androgen receptor ligand binding domain |
| 04/19/2001 | CA2388053A1 Cationic dosper virosomes |
| 04/19/2001 | CA2387545A1 Methods of treating or preventing cell, tissue, and organ damage using human myeloid progenitor inhibitory factor-1 (mpif-1) |
| 04/19/2001 | CA2387541A1 Short segments of dap-kinase |
| 04/19/2001 | CA2387314A1 Compositions and methods of use of ligands that bind components of the blood coagulation/clotting pathway for the treatment of cancer and angiogenic-based disease |
| 04/19/2001 | CA2387234A1 Hair and scalp treatment method and recipes for application of this method |
| 04/19/2001 | CA2387199A1 Remedies for intractable wound |
| 04/19/2001 | CA2387145A1 Liposome encapsulated silver salt compositions |
| 04/19/2001 | CA2386299A1 Antiprotozoal histone acetyl transferase inhibitors |
| 04/19/2001 | CA2385907A1 Methods to identify compounds that modulate neuronal activity |